Tumor Stage Mycosis Fungoides in a Patient Treated with Long‐Term Corticosteroids for Asthma and Atopic‐Like Dermatitis

Abel, Elizabeth A.; Nickoloff, Brian J.; Shelby, Dan; Watson, Wade; Wood, Gary S.

doi:10.1111/j.1524-4725.1986.tb02088.x

Cited by 17 publications

(12 citation statements)

References 25 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because some cases of CTCL are preceded by a chronic dermatitis or AD (Rajka and Winkelmann, 1984;Abel et al, 1986;van Haselen et al, 1999), it seems plausible that the increased usage of Vb5.1 in leukemic CTCL may be because neoplastic transformation is more likely to involve a subset of Vb5.1 þ skin-homing T cells that is more numerous relative to other Vb segments. Perhaps bacterial SAg play a role in the selection of Vb5.1 neoplastic clones.…”

Section: Discussionmentioning

confidence: 97%

Evidence for Restricted Vβ Usage in the Leukemic Phase of Cutaneous T Cell Lymphoma

Vonderheid

Boselli

Conroy

et al. 2005

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Antibodies directed against the beta chain of the T cell receptor (anti-Vbeta antibodies) are useful to identify the Vbeta repertoire of T cells in various diseases and to quantify numbers of Vbeta-bearing T cells. The goals of this study were to identify Vbeta+ cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the percentage of positive calls with other measures of blood tumor burden, i.e., lymphocyte subsets with a CD4+CD7- and CD4+CD26- phenotype and Sezary cell counts. Thirty-three of 49 (67%) cases of leukemic CTCL reacted with an anti-Vbeta antibody. When combined with reports from the literature, the frequency of Vbeta5 (probably Vbeta5.1) usage was relatively high when compared with Vbeta2 that is also frequently expressed by normal CD4+ T cells. The percentage of Vbeta+ cells correlated to the percentage of CD4+CD7- and CD4+CD26- cells for cases in which the neoplastic cells were deficient in expression of CD7 and CD26, respectively, but not the Sezary cell count. We hypothesize that the increased Vbeta5.1 usage in CTCL may be the result of depletion of Vbeta2 and other Vbeta-bearing T cells by staphylococcal superantigens prior to neoplastic transformation, resulting in a relative increase in the frequency of Vbeta5.1 usage in CTCL.

show abstract

Section: Discussionmentioning

confidence: 97%

Evidence for Restricted Vβ Usage in the Leukemic Phase of Cutaneous T Cell Lymphoma

Vonderheid

Boselli

Conroy

et al. 2005

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…[7][8][9] However, in the absence of TCR gene analysis, it is difficult to know whether the eczematous lesions represented patch-stage cutaneous Tcell lymphoma (mycosis fungoides). All of our patients had active eczema at the time they developed their CD30 + lymphoma, and it was possible to exclude a diagnosis of erythrodermic cutaneous T-cell lymphoma by biopsy and/or TCR gene analysis.…”

Section: Casementioning

confidence: 99%

CD30+ Cutaneous Lymphoma in Association With Atopic Eczema

Fletcher

Orchard²,

Hubbard³

et al. 2004

Arch Dermatol

View full text Add to dashboard Cite

Background: Chronic atopic eczema is not regarded as a precursor of malignancy, and, to our knowledge, there has been only one previous case report of CD30 + cutaneous lymphoma in association with atopic dermatitis.Observations: We report 4 cases of CD30 + lymphoproliferative disease in young adult patients with active atopic eczema dating from early childhood. Three patients developed primary cutaneous anaplastic large cell lymphoma, of whom 2 developed systemic disease and 1 died. The other patient developed lymphomatoid papulosis type A, which resolved after withdrawal of cyclosporine therapy. No other patient had received immunosuppressive therapy.

show abstract

“…4 A few case reports have described patients who developed cutaneous lymphoma after having long-standing disease. 5,6 In an attempt to assess the risk of developing skin cancer for patients with AD, we performed a retrospective cohort study of patients hospitalized for AD in Sweden from 1965 to 1999. The risk of developing cancers other than skin cancer was also investigated because an impaired immune system, microbial infections or colonizations, a long-standing inflammation, or treatments for these conditions might conceivably increase the risk of malignant transformation in organs other than the skin.…”

mentioning

confidence: 99%

Incidence of Cancer Among Patients With Atopic Dermatitis

Hagströmer¹,

Ye²,

Nyrén³

et al. 2005

Arch Dermatol

139

View full text Add to dashboard Cite

Interventions:The National Swedish Cancer Register coded malignant neoplasms during the entire period of study. Follow-up time was calculated from the date of entry in the cohort until the occurrence of a first cancer diagnosis, emigration, death, or the end of the observation period, whichever occurred first.Main Outcome Measures: Follow-up by means of record linkages to several nationwide registers, among them the National Swedish Cancer Register. Standardized incidence ratios (SIRs) (the ratios of numbers of observed patients with cancer to expected numbers of incident cases of cancer) estimated the risk of developing cancer rela-tive to the risks in the age-, sex-, and calendar yearmatched general Swedish population.Results: After excluding the first year of follow-up, the risk of developing any cancer was increased by 13% (95% confidence interval [CI] of SIR, 1.01-1.25, based on 311 observed patients with cancer). Excess risks were observed for cancers of the esophagus (SIR, 3.5; 95% CI, 1.3-7.7; 6 patients), pancreas (SIR, 1.9; 95% CI, 1.0-3.4; 11 patients), brain (SIR, 1.6; 95% CI, 1.1-2.4; 27 patients), and lung (SIR, 2.0; 95% CI, 1.3-2.8; 31 patients) and for lymphoma (SIR, 2.0; 95% CI, 1.4-2.9; 29 patients). There was a nonsignificant 50% excess risk for nonmelanoma skin cancer (SIR, 1.5; 95% CI, 0.8-2.6; 12 patients), seemingly confined to men and to the first 10 years of follow-up. Malignant melanoma did not occur more often than expected. Conclusions:The observed risk elevations, all of borderline statistical significance, should be interpreted cautiously. We could not control for possible confounding by cases of cancer caused by smoking, and the combination of multiple significance testing and few observed patients may have generated chance findings.

show abstract

Tumor Stage Mycosis Fungoides in a Patient Treated with Long‐Term Corticosteroids for Asthma and Atopic‐Like Dermatitis

Cited by 17 publications

References 25 publications

Evidence for Restricted Vβ Usage in the Leukemic Phase of Cutaneous T Cell Lymphoma

Evidence for Restricted Vβ Usage in the Leukemic Phase of Cutaneous T Cell Lymphoma

CD30+ Cutaneous Lymphoma in Association With Atopic Eczema

Incidence of Cancer Among Patients With Atopic Dermatitis

Contact Info

Product

Resources

About